Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dyslexia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2006 by University Hospital Muenster.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University Hospital Muenster
ClinicalTrials.gov Identifier:
NCT00111371
First received: May 19, 2005
Last updated: April 18, 2007
Last verified: September 2006

May 19, 2005
April 18, 2007
January 2005
Not Provided
  • Boost in training success (percent correct) through levodopa as compared to placebo
  • Boost in training success (reaction times) through levodopa as compared to placebo
  • Increased performance on reading, spelling and writing tests in dyslexic patients treated with levodopa as compared to placebo
Same as current
Complete list of historical versions of study NCT00111371 on ClinicalTrials.gov Archive Site
Stability of improvements one month post training
Same as current
Not Provided
Not Provided
 
Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dyslexia
Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Dyslexia)

This study aims to determine whether levodopa, in combination with a high frequency training of (grammatical) rules, is effective in boosting learning success in healthy subjects and whether this kind of training in combination with levodopa improves reading and spelling abilities of patients with dyslexia.

Prior work by our group shows that d-amphetamine and the dopamine precursor levodopa markedly improve word learning success in healthy subjects. In this randomized, placebo-controlled, double-blind trial, we probe whether daily administration of levodopa, coupled with a training of grammatical rules, improves the training success in healthy adults as compared to placebo administration. In the second step of this study, patients with dyslexia will be trained with the identical protocol. We postulate that the combination of intensive training in language rules and levodopa improves the reading, writing, and spelling abilities of patients with dyslexia.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Dyslexia
Drug: Levodopa
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
October 2007
Not Provided

Inclusion Criteria:

  • Right-handedness
  • Age between 18-35 years
  • Primary language: German

Exclusion Criteria:

  • Known allergy to levodopa or tetrazine
  • History of medication/drug abuse
  • Acute nicotine withdrawal or > 10 cigarettes per day
  • >6 cups/glasses of coffee, caffeine drinks or energy drinks per day
  • >50 grams of alcohol per day
  • Hypertonia
  • Arteriosclerosis
  • Diabetes, asthma, or glaucoma
  • Psychiatric disease
  • Neurologic disease
  • Other medication
Male
18 Years to 35 Years
Yes
Contact: Stefan Knecht, MD +49-251-83 ext 48195 knecht@uni-muenster.de
Germany
 
NCT00111371
LL-001; Project on Dyslexia
Not Provided
Not Provided
University Hospital Muenster
Not Provided
Principal Investigator: Stefan Knecht, Prof. Dr. Dept. of Neurology, Universityclinic of Muenster
University Hospital Muenster
September 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP